Gilead shareholders elect all nine directors, approve equity plan increase, reject three proposals

GILEAD SCIENCES, INC.

All nine director nominees elected; Daniel O'Day received 980.6M votes for, 50.2M against.
Ernst & Young ratified as auditor for FY 2026: 1,046.4M for, 82.8M against, 1.0M abstain.
Say-on-pay approved with 954.3M for (92.6% of votes cast excluding broker non-votes).
Amended 2022 Equity Incentive Plan approved, adding 47.75M new shares to the pool.
Shareholder proposals on independent chair, patent exclusivity, and ESG metrics all defeated by wide margins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.